Helping to fight Covid-19

How we are contributing to the global Covid-19 response.


Global fight against Covid-19
Merck/EFPIA video. We Won’t Rest to serving patients, scientists and healthcare providers

At Merck we are supporting from many ways the global fight against Covid-19. From protection, prevention and treatment, colleagues from healthcare, life science and performance materials are a key part of our joint efforts against pandemic.

Committed to fight Covid-19

290k

units of interferon beta-1a (Rebif®) donated to the World Health Organization

150k

liters of disinfectants made available to the state of Hesse

  1. Press Releases

    Merck KGaA, Darmstadt, Germany statement on Rebif® (interferon beta-1a) contribution ...

    As part of the global effort to investigate potential COVID-19 therapeutics and our support of independent research, Merck KGaA, Darmstadt, Germany is collaborating with the US National Institute of Allergy ...

    2020/08/05

  2. Press Releases

    New Report Identifies Paths to Pandemic Resilience

    A new report details potential paths to solutions to overcoming the global Covid-19 crisis and ways to prepare for or even prevent a future pandemic.

    2020/07/01

  3. Press Releases

    Merck KGaA, Darmstadt, Germany, Initiates First Clinical Trial of TLR7 and ...

    Merck KGaA, Darmstadt, Germany today announced the U.S. Food and Drug Administration (FDA) has cleared its investigational new drug application for M5049 for the treatment of patients with Covid-19 pneumonia.

    2020/06/25

Cooperation with IAVI and Serum Institute of India

Together with nonprofit scientific research organization IAVI and biologics manufacturer Serum Institute of India we aim to develop monoclonal antibodies to address Covid-19.

A Phase I clinical trial is expected to start early in 2021. The SARS-CoV-2 neutralizing antibodies were co-invented by IAVI and Scripps Research.
More information is available here.

We collaborate with the Bill & Melinda Gates Foundation to fight COVID-19

On March 26, a consortium of healthcare and life sciences companies together with the Bill & Melinda Gates Foundation announced an important collaboration to accelerate the development, manufacture, and delivery of vaccines, diagnostics, and treatments for Covid-19. We are proud to be part of this group. All partners contribute a range of assets, resources, and expertise needed to identify effective and scalable solutions to the pandemic, which is affecting billions worldwide.
More information is available here.

On September 30 we reinforced our collaboration by signing an agreement to help accelerate the end of the pandemic. This communique reflects the joint commitment on behalf of 15 life science and healthcare companies and the Bill Melinda Gates Foundation to enhance access for everyone around the world to Covid-19 vaccines, therapeutics, and diagnostics, regardless of their income.
More information is available here.

Garijo Belen 02 Cut Out 600 600 Garijo Belen 02 Cut Out 600 600

Human progress is what we stand for. During these difficult times, we actively contribute resources, full dedication and expertise to fight this COVID-19 pandemic.

Belén Garijo

Vice Chair of the Executive Board,

Deputy CEO of Merck KGaA, Darmstadt, Germany & CEO Healthcare

Redirect

You have accessed https://www.emdgroup.com, but for users from your part of the world, we originally designed the following web presence https://www.merckgroup.com.

Let's go

Internet Explorer is not supported

You are using an outdated browser. If you would like to use our website, please use Chrome, Firefox, Safari or other browser

Share Disclaimer

By sharing this content, you are consenting to share your data to this social media provider. More information are available in our Privacy Statement